newsfilter
← Latest News
GlobeNewswire·

iBio and AstralBio Provide Update on Myostatin Program for Obesity

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and